Blepharoptosis

What is the diagnosis and what treatment is indicated? The diagnosis is eyelid ptosis, which means drooping of the upper eyelid. This may reduce quality of life by affecting the upper visual field and interfering with daily activities such as driving and reading. It may also cause forehead muscle fatigue, neck pain, a sad or tired appearance, eyelid asymmetry, and forehead wrinkles. The only treatment to correct eyelid ptosis is surgery. In the present case, the indicated procedure consists of reinserting the tendon of the upper eyelid levator muscle into the original position on the tarsus. This is performed using sutures to attach the tendon to the tarsus. Two types of sutures may be used: absorbable sutures, which are absorbed by the body over approximately 2-3 months, and non-absorbable sutures, which remain permanently in the eyelid because the body cannot break them down. Why is this study being conducted? The surgery that participants will undergo is part of the standard treatment for eyelid ptosis. Both types of suture material used in this procedure are routinely used in clinical practice, meaning that either type could be used regardless of participation in the study. Some previous studies suggest that non-absorbable sutures may maintain eyelid elevation better in the long term and reduce the need for further surgery compared with absorbable sutures. However, there is currently insufficient evidence to establish this with certainty. Most previous studies have evaluated patients who had already been treated rather than prospectively comparing both types of sutures through a randomized clinical trial, which may introduce bias when interpreting the results. Therefore, there is currently insufficient scientific evidence to determine with certainty which suture material provides better results, and both materials continue to be routinely used in clinical practice. The aim of this study is to compare both types of suture under controlled conditions through a randomized controlled trial, in order to determine the outcomes associated with each type of suture in the medium and long term. How will the type of suture be determined? If a participant agrees to participate, the type of suture used during surgery will be assigned randomly by a computerized randomization system. Neither the participant nor the surgeon will be able to choose the type of suture. Both suture materials are routinely used in clinical practice and are authorized for this type of surgery. The only difference between the two study groups will be the material used to attach the upper eyelid levator tendon to the tarsus. Participants will not be informed which type of suture was used during surgery, although this information may be accessed if medically necessary. What does the procedure involve? The surgery will be performed in an operating room by ophthalmologists specialized in eyelid surgery. The procedure will be performed under local anesthesia with light sedation. This is an outpatient procedure and does not require hospital admission. The procedure lasts approximately 45-60 minutes. If removal of excess skin is required in a particular case, this will be performed during the same procedure. Anterior white-line (levator tendon) advancement through the skin produces a scar within the eyelid crease. This is generally a cosmetic and well-tolerated scar. Five visits will be required for appropriate follow-up, which is the same number of visits that would be required without participation in the study: the initial visit, the day of surgery, and three follow-up visits at 2 weeks, 3 months, and 7 months. Participation in this study does not involve any additional risk from supplementary tests. During the study, photographs of the periocular area and face will be taken to evaluate the surgical outcomes. These images will be treated as personal health data. If a participant decides to participate, the participant will be asked to sign an Informed Consent Form. Participation will involve allowing information from the medical record to be collected, consenting to relevant clinical photographs, and attending the scheduled follow-up visits. The study will be conducted at Hospital Rey Juan Carlos and aims to include 58 patients with the same condition.

To develop a feedback-enabled magnetic device for management of blepharoptosis and evaluate its efficacy and safety, including the gain of palpebral fissure height, visual field obstruction, blurred vision, foreign body sensation over the cornea, burning or hot sensation over facial skin, and erythema or pruritus over the eyelid, by performing a human trial on patients with blepharoptosis.

Intravitreal anti-VEGF injections are a mainstay of treatment for retinal diseases such as neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion, and usually require repeated administration over years. During each injection an eyelid speculum holds the lids open and the upper eyelid is exposed to repeated mechanical stretch. Aponeurotic ptosis after intraocular surgery is well described, but evidence on blepharoptosis after repeated intravitreal injections is limited and conflicting. This single-center prospective observational study enrolls 60 patients who are starting intravitreal anti-VEGF therapy in one eye only; the untreated fellow eye of each patient serves as an internal control. Upper eyelid position and function are assessed with margin reflex distance-1 (MRD-1), margin reflex distance-2 (MRD-2) and levator function at baseline and at months 1, 3, 6 and 12. The primary endpoint is the difference between the injected eye and the fellow eye in the change in MRD-1 from baseline to month 12.

This is a Phase III Study to evaluate the efficacy and safety of STN1013800 Ophthalmic Solution in Chinese Patients with Acquired Blepharoptosis. At present, there are no medicines for the treatment of acquired blepharoptosis in China. Therefore, to evaluate the efficacy and safety of 0.1% STN1013800 ophthalmic solution, Vehicle (Placebo) are designed. For the screening period, 3-7 days were set to confirm the subjects and judge their qualification. Dosage and administration were based on prior clinical trial results approved at 0.1% once daily for 42 days treatment.